ENABLEX DIN 02273225
Status: Marketed
Holder: SEARCHLIGHT PHARMA INC
Molecule: DARIFENACIN (DARIFENACIN HYDROBROMIDE)
Available to quote
Health Canada record
| Active ingredient(s) | DARIFENACIN (DARIFENACIN HYDROBROMIDE) 15 MG |
|---|---|
| Dosage form | Tablet (Extended-Release) |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | G04BD10 DARIFENACIN |
| Original market date | 06-Apr-2006 |
| Current status date | 02-Apr-2019 |
| Source | Health Canada DPD |
Establishment licence of the holder
Searchlight Pharma Inc — licence 102247, currently licensed, last inspection rating C (2024-10-10).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DARIFENACIN (DARIFENACIN HYDROBROMIDE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02452510 | APO-DARIFENACIN | APOTEX INC | Tablet (Extended-Release) | DARIFENACIN (DARIFENACIN HYDROBROMIDE) 7.5 MG | Marketed |
| 02452529 | APO-DARIFENACIN | APOTEX INC | Tablet (Extended-Release) | DARIFENACIN (DARIFENACIN HYDROBROMIDE) 15 MG | Marketed |
| 02273217 | ENABLEX | SEARCHLIGHT PHARMA INC | Tablet (Extended-Release) | DARIFENACIN (DARIFENACIN HYDROBROMIDE) 7.5 MG | Marketed |
| 02491869 | JAMP DARIFENACIN | JAMP PHARMA CORPORATION | Tablet (Extended-Release) | DARIFENACIN (DARIFENACIN HYDROBROMIDE) 7.5 MG | Marketed |
| 02491877 | JAMP DARIFENACIN | JAMP PHARMA CORPORATION | Tablet (Extended-Release) | DARIFENACIN (DARIFENACIN HYDROBROMIDE) 15 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 21842 | 2019-02-11 | New Drug Submission (NDS) | A CHANGE IN PRODUCT OWNERSHIP FROM MJERUS LABS TO SEARCHLIGHT PHARMA INC., AND TO ADD A PVC-PVDC WITH ALUMINUM FOIL BLISTER PACK OF 7 TABLETS FOR THE 7.5 MG TABLET |
| 14290 | 2013-04-16 | New Drug Submission (NDS) | Manufacturer name change |
| 7610 | 2005-11-14 | New Drug Submission (NDS) |